Your browser doesn't support javascript.
loading
Recent progress in direct-acting antiviral agents for chronic hepatitis C / 临床肝胆病杂志
Journal of Clinical Hepatology ; (12): 493-495, 2014.
Article in Chinese | WPRIM | ID: wpr-498959
ABSTRACT
The current standard treatment for hepatitis C virus (HCV)infection is a combination of pegylated interferon (PEG-IFN)and ribavirin.However,it remains incurable in some patients.In recent years,direct acting antiviral agents (DAAs)that target specific HCV enzymes in HCV life cycle have been developed rapidly.A combination of PEG-IFN,ribavirin,and DAAs can increase the sustained viro-logical response rate in patients with chronic hepatitis C (CHC).For patients who cannot use or tolerate interferon therapy,a combination of various DAAs has good efficacy.Therefore,DAAs bring new hope for the treatment of CHC.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Clinical Hepatology Year: 2014 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Clinical Hepatology Year: 2014 Type: Article